More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.

One participant lost 22% of her weight in nine months — substantially faster than the rate seen with approved GLP-1 drugs ...

President Donald Trump and HHS Secretary Robert F. Kennedy Jr. said they will be studying the "threat" to children posed by ...

Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug ...

Shares of obesity-drug maker Novo Nordisk rose Friday after the Food and Drug Administration declared that the company’s popular medications Ozempic and Wegovy were no longer in shortage. A shortage o ...

How can we best treat infectious diseases in people with obesity? Hospital pharmacist and Ph.D. researcher Koen van Rhee ...

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...

Zealand’s CEO Adam Steensberg said that the company is “exactly where it wants to be” in terms of its partnering and ...

Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.

A telehealth company partnered with a pharmacy that lacked a required license, raising doubts about the safety and efficacy ...

The FDA has removed semaglutide from its drug shortage list after the agency determined the current supply of the drug can ...

In ongoing trials of Eli Lilly’s (LLY) next-generation obesity drug, several trial participants are losing too much weight, STAT’s Elaine Chen ...